Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients

Thomas Gerald,Vitaly Margulis,Xiaosong Meng,Aditya Bagrodia,Suzanne Cole,Qian Qin, S Greg Call,Elizabeth Mauer,Yair Lotan,Solomon L Woldu

Urologic Oncology: Seminars and Original Investigations（2023）

引用 1|浏览3

暂无评分

摘要

•Therapeutic targeting in bladder cancer may improve outcomes.•Broad array of somatic genetic mutations do not differ by stage of bladder cancer.•Specifically, HRR gene, TMB, PD-L1, MSI, and FGFR status do not differ by stage.•Germline mutations in bladder cancer are rare and do not differ by stage.•Personalized, targeted therapy should be explored at all bladder cancer stages.

查看译文

关键词

Bladder cancer,Urothelial carcinoma,Somatic mutation,Germline mutation,Actionable genetic target

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要